Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 172 clinical trials
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib plus avelumab) works in treating patients with non-squamous non-small cell lung cancer that has an STK11 gene mutation and has come back (recurrent) or is stage IV. Talazoparib may stop the growth of tumor cells by blocking some …

targeted therapy
hepatitis c virus
tumor cells
ct scan
concurrent chemotherapy
  • 33 views
  • 25 Jan, 2021
  • 250 locations
Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as …

tumor cells
ct scan
pemetrexed
metastasis
neuropathy
  • 99 views
  • 27 Jan, 2021
  • 7 locations
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients with non-small cell lung cancer that is stage IV or has come back. Immunotherapy with monoclonal antibodies, such as ramucirumab and pembrolizumab, may help the body's immune system attack …

hepatitis c virus
liver metastases
insulin
metastasis
oral contraceptive pill
  • 80 views
  • 25 Jan, 2021
  • 629 locations
PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

Background Drugs known as PARP inhibitors are known to help stop tumor growth in patients with breast, ovarian cancers and many other cancers including prostate and pancreatic cancers. Many research studies done in animals and human cells have shown that these type of drugs can improve how well chemotherapy works. …

brain metastases
ovarian cancer
neutrophil count
measurable disease
metastasis
  • 0 views
  • 02 Feb, 2021
  • 1 location
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver Gastrointestinal Endocrine and Skin Toxicity

This is a prospective cohort study aiming to establish clinical and biological risk factors of immune-checkpoint inhibitors (ICIs) mediated toxicity. ICIs have recently revolutionized cancer treatment and already considered as a new standard of care for lung cancer, renal carcinoma, melanoma and hepatocellular carcinoma. However, the variability in response rates …

  • 0 views
  • 11 Apr, 2021
  • 2 locations
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy

To determine treatment response to surgical debulking and intra-operative Intraperitoneal Hyperthermic Chemotherapy (IPHC) in patients with the following malignancies: Gynecologic cancers (ovarian, primary peritoneal or fallopian tube, and uterine/cervical cancers). Mesotheliomas. GI cancers (Gallbladder, liver, small intestine, pancreas, stomach, colon, appendix). To monitor the toxicities and complications of this treatment …

cancer
renal function
treatment regimen
cavity
ovarian cancer
  • 95 views
  • 23 Jan, 2021
  • 1 location
Immunotherapy Chemotherapy Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC

A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy plus stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour, in patients with histologically-confirmed synchronous oligo-metastatic non-small cell lung cancer (NSCLC).

stage iv non-small cell lung cancer
carboplatin
lung carcinoma
metastasis
durvalumab
  • 0 views
  • 27 Jan, 2021
  • 12 locations
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Lung cancer is the leading cause of cancer-related death in the United States. Most people with lung cancer are already in the advanced stages of the disease by the time they see a doctor. Researchers want …

targeted therapy
brain metastases
cancer
stage iv non-small cell lung cancer
metastasis
  • 21 views
  • 26 Jan, 2021
  • 1 location
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Lung cancer remains the most lethal malignancy in both sexes around the world. It is estimated that lung cancer caused 234,030 deaths in the United States in 2016, accounting for 28% of all cancer-related deaths. In 2012 alone, a total of 6,697 deaths from lung cancer were registered in Mexico; …

  • 0 views
  • 18 Feb, 2021
  • 1 location
A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea

The purpose of this study is to estimate the cumulative incidence of all adverse events (AEs), including serious adverse events (SAEs), adverse event of special interest (AESI), among participants who have been administered niraparib as per the approved indications.

niraparib
platinum-based chemotherapy
cancer chemotherapy
fallopian tube
cancer of the ovary
  • 0 views
  • 25 Jan, 2021
  • 1 location